357 related articles for article (PubMed ID: 18436784)
1. Efficient inhibition of the Alzheimer's disease beta-secretase by membrane targeting.
Rajendran L; Schneider A; Schlechtingen G; Weidlich S; Ries J; Braxmeier T; Schwille P; Schulz JB; Schroeder C; Simons M; Jennings G; Knölker HJ; Simons K
Science; 2008 Apr; 320(5875):520-3. PubMed ID: 18436784
[TBL] [Abstract][Full Text] [Related]
2. Membrane anchored and lipid raft targeted β-secretase inhibitors for Alzheimer's disease therapy.
Ben Halima S; Rajendran L
J Alzheimers Dis; 2011; 24 Suppl 2():143-52. PubMed ID: 21460437
[TBL] [Abstract][Full Text] [Related]
3. Secretase inhibitors and modulators for Alzheimer's disease treatment.
Tomita T
Expert Rev Neurother; 2009 May; 9(5):661-79. PubMed ID: 19402777
[TBL] [Abstract][Full Text] [Related]
4. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and beta-secretase.
Zhu Y; Xiao K; Ma L; Xiong B; Fu Y; Yu H; Wang W; Wang X; Hu D; Peng H; Li J; Gong Q; Chai Q; Tang X; Zhang H; Li J; Shen J
Bioorg Med Chem; 2009 Feb; 17(4):1600-13. PubMed ID: 19162488
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological evidences for DFK167-sensitive presenilin-independent gamma-secretase-like activity.
Sevalle J; Ayral E; Hernandez JF; Martinez J; Checler F
J Neurochem; 2009 Jul; 110(1):275-83. PubMed ID: 19457123
[TBL] [Abstract][Full Text] [Related]
7. Gamma-secretase: a complex target for Alzheimer's disease.
Lundkvist J; Näslund J
Curr Opin Pharmacol; 2007 Feb; 7(1):112-8. PubMed ID: 17169612
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease.
Kreft AF; Martone R; Porte A
J Med Chem; 2009 Oct; 52(20):6169-88. PubMed ID: 19694467
[No Abstract] [Full Text] [Related]
9. Aspartic proteases involved in Alzheimer's disease.
Schmidt B
Chembiochem; 2003 May; 4(5):366-78. PubMed ID: 12740808
[TBL] [Abstract][Full Text] [Related]
10. Rac1 changes the substrate specificity of gamma-secretase between amyloid precursor protein and Notch1.
Boo JH; Sohn JH; Kim JE; Song H; Mook-Jung I
Biochem Biophys Res Commun; 2008 Aug; 372(4):913-7. PubMed ID: 18538664
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of gamma-secretase activity reduces Abeta production, reduces oxidative stress, increases mitochondrial activity and leads to reduced vulnerability to apoptosis: Implications for the treatment of Alzheimer's disease.
Sheng B; Gong K; Niu Y; Liu L; Yan Y; Lu G; Zhang L; Hu M; Zhao N; Zhang X; Tang P; Gong Y
Free Radic Biol Med; 2009 May; 46(10):1362-75. PubMed ID: 19264123
[TBL] [Abstract][Full Text] [Related]
12. Design of potent inhibitors of human beta-secretase. Part 2.
Freskos JN; Fobian YM; Benson TE; Moon JB; Bienkowski MJ; Brown DL; Emmons TL; Heintz R; Laborde A; McDonald JJ; Mischke BV; Molyneaux JM; Mullins PB; Bryan Prince D; Paddock DJ; Tomasselli AG; Winterrowd G
Bioorg Med Chem Lett; 2007 Jan; 17(1):78-81. PubMed ID: 17049233
[TBL] [Abstract][Full Text] [Related]
13. Design of potent inhibitors of human beta-secretase. Part 1.
Freskos JN; Fobian YM; Benson TE; Bienkowski MJ; Brown DL; Emmons TL; Heintz R; Laborde A; McDonald JJ; Mischke BV; Molyneaux JM; Moon JB; Mullins PB; Bryan Prince D; Paddock DJ; Tomasselli AG; Winterrowd G
Bioorg Med Chem Lett; 2007 Jan; 17(1):73-7. PubMed ID: 17046251
[TBL] [Abstract][Full Text] [Related]
14. Regulation of gamma-secretase activity in Alzheimer's disease.
Zhou S; Zhou H; Walian PJ; Jap BK
Biochemistry; 2007 Mar; 46(10):2553-63. PubMed ID: 17298085
[TBL] [Abstract][Full Text] [Related]
15. Effects of sulindac sulfide on the membrane architecture and the activity of gamma-secretase.
Gamerdinger M; Clement AB; Behl C
Neuropharmacology; 2008 May; 54(6):998-1005. PubMed ID: 18359496
[TBL] [Abstract][Full Text] [Related]
16. Designed helical peptides inhibit an intramembrane protease.
Das C; Berezovska O; Diehl TS; Genet C; Buldyrev I; Tsai JY; Hyman BT; Wolfe MS
J Am Chem Soc; 2003 Oct; 125(39):11794-5. PubMed ID: 14505382
[TBL] [Abstract][Full Text] [Related]
17. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
18. Why does beta-secretase zymogen possess catalytic activity? Molecular modeling and molecular dynamics simulation studies.
Zuo Z; Gang C; Zou H; Mok PC; Zhu W; Chen K; Jiang H
Comput Biol Chem; 2007 Jun; 31(3):186-95. PubMed ID: 17500040
[TBL] [Abstract][Full Text] [Related]
19. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition.
Abramowski D; Wiederhold KH; Furrer U; Jaton AL; Neuenschwander A; Runser MJ; Danner S; Reichwald J; Ammaturo D; Staab D; Stoeckli M; Rueeger H; Neumann U; Staufenbiel M
J Pharmacol Exp Ther; 2008 Nov; 327(2):411-24. PubMed ID: 18687920
[TBL] [Abstract][Full Text] [Related]
20. Boom in the development of non-peptidic beta-secretase (BACE1) inhibitors for the treatment of Alzheimer's disease.
Silvestri R
Med Res Rev; 2009 Mar; 29(2):295-338. PubMed ID: 18651582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
